Study #2024-0185
A single-arm, multicenter phase 2 study of neoadjuvant pembrolizumab with trastuzumab and chemotherapy in resectable HER2+ esophagogastric tumors
MD Anderson Study Status
Enrolling
Treatment Agent
Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Description
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation
Study phase:
Phase II
Physician name:
Jenny Li
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-833-559-2966
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.